Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue 8, 2002, Pages 889-896

  Ladhams, Andrew ^a   Schmidt, Chris ^b   Sing, Garwin ^a   Butterworth, Lesley ^a   Fielding, George ^c   Tesar, Paul ^c   Strong, Russell ^d   Leggett, Barbara ^c   Powell, Lawrie ^b   Maddern, Guy ^e   Ellem, Kay ^b   Cooksley, Graham ^a  

^a Royal Brisbane and Womens Hospital Research Foundation   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d PRINCESS ALEXANDRA HOSPITAL   (Australia)

^e Queen Elizabeth II Hospital   (Australia)

Author keywords

Dendritic cells; Hepatocellular carcinoma; Immunotherapy

Indexed keywords

TUMOR ANTIGEN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOTRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGING; IMMUNE RESPONSE; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0036378352     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2002.02817.x     Document Type: Article

References (24)

1. Okuda K. Hepatocellular carcinoma. J. Hepatol. 2000; 32 (Suppl. 1): 225-37.
2. Nakakura EK, Choti MA. Management of hepatocellular carcinoma. Oncology 2000; 14: 1085-98.
3. Ellem KA, Schmidt CW, Li CL et al. The labyrinthine ways of cancer immunotherapy: T cell, tumor cell encounter: 'How do I lose thee? Let me count the ways'. Adv. Cancer Res. 1998; 75: 203-49.
4. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LDJ. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 1996; 183: 283-7.
5. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 1994; 12: 337-65.
6. Kawata A, Une Y, Hosokawa M, Uchino J, Kobayashi H. Tumor-infiltrating lymphocytes and prognosis of hepatocellular carcinoma. Jpn J. Clin. Oncol. 1992; 22: 256-63.
7. Haruta I, Yamauchi K, Aruga A et al. Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: Comparison between LAK cell and CTL therapy. J. Immunother. Emphasis Tumor Immunol. 1996; 19: 218-23.
8. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 1999; 50: 507-29.
9. Gunzer M, Janich S, Varga G, Grabbe S. Dendritic cells and tumor immunity. Semin. Immunol. 2001; 13: 291-302.
10. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med. 1973; 137: 1142-62.
11. Lopez JA, Hart DN. Current issues in dendritic cell cancer immunotherapy. Curr. Opin. Mol. Ther. 2002; 4: 54-63.
12. DeMatos P, Abdel-Wahab Z, Vervaert C, Seigler HF. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell. Immunol. 1998; 185: 65-74.
13. Friedl J, Stift A, Paolini P et al. Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes in human hepatocellular cancer. Cancer Biother. Radiopharm. 2000; 15: 477-86.
14. Kakumu S, Ito S, Ishikawa T et al. Decreased function of peripheral blood dendritic cells in patients with hepatocellular carcinoma with hepatitis B and C virus infection. J. Gastroenterol. Hepatol. 2000; 15: 431-6.
15. Chen S, Akbar SM, Tanimoto K et al. Absence of CD83-positive mature and activated dendritic cells at cancer nodules from patients with hepatocellular carcinoma: Relevance to hepatocarcinogenesis. Cancer Lett. 2000; 148: 49-57.
16. Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji M. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J. Hepatol. 1999; 31: 323-31.
17. Peters JH, Xu H, Ruppert J, Ostermeier D, Friedrichs D, Gieseler RK. Signals required for differentiating dendritic cells from human monocytes in vitro. Adv. Exp. Med. Biol. 1993; 329: 275-80.
18. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J. Immunol. Methods 1996; 196: 121-35.
19. Thurner B, Roder C, Dieckmann D et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J. Immunol. Methods 1999; 223: 1-15.
20. Sing GK, Ladhams A, Arnold S et al. A longitudinal analysis of cytotoxic T lymphocyte precursor frequencies to the hepatitis B virus in chronically infected patients. J. Viral Hepatol. 2001; 8: 19-29.
21. Battegay M, Fikes J, Di Bisceglie AM et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J. Virol. 1995; 69: 2462-70.
22. Steven NM, Leese AM, Annels NE, Lee SP, Rickinson AB. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J. Exp. Med. 1996; 184: 1801-13.
23. Fazekas de St Groth S. The evaluation of limiting dilution analysis. J. Immunol. Methods 1982; 49: 11-23.
24. Seymour K, Pettit S, O'Flaherty E, Charnley RM, Kirby JA. Selection of metastatic tumour phenotypes by host immune systems. Lancet 1999; 354: 1989-91.